Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort
Journal of Neurology · 2024
DOI: 10.1007/s00415-024-12221-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2024. Verfasst von Elisa Canu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Amyloid beta-Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministero della Salute, Fondation pour la Recherche sur Alzheimer.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: The AT(N) classification system stratifies patients based on biomarker profiles, including amyloid-beta deposition (A), tau pathology (T), and neurodegeneration (N). This study aims to apply the AT(N) classification to a hospital-based cohort of patients with cognitive decline and/or dementia, within and outside the Alzheimer's disease (AD) continuum, to enhance our understanding of the multidimensional aspects of AD and related disorders. Furthermore, we wish to investigate how many cases from our cohort would be eligible for the available disease modifying treatments, such as aducanemab and lecanemab. METHODS: We conducted a retrospective evaluation of 429 patients referred to the Memory Center of IRCCS San Raffaele Hospital in Milan. Patients underwent clinical/neuropsychological assessments, lumbar puncture, structural brain imaging, and positron emission tomography (FDG-PET). Patients were stratified according to AT(N) classification, group comparisons were performed and the number of eligible cases for anti-β amyloid monoclonal antibodies was calculated. RESULTS: Sociodemographic and clinical features were similar across groups. The most represented group was A + T + N + accounting for 38% of cases, followed by A + T - N + (21%) and A - T - N + (20%). Although the clinical presentation was similar, the A + T + N + group showed more severe cognitive impairment in memory, language, attention, executive, and visuospatial functions compared to other AT(N) groups. Notably, T + patients demonstrated greater memory complaints compared to T - cases. FDG-PET outperformed MRI and CT in distinguishing A + from A - patients. Although 61% of the observed cases were A + , only 17% of them were eligible for amyloid-targeting treatments. DISCUSSION: The AT(N) classification is applicable in a real-world clinical setting. The classification system provided insights into clinical management and treatment strategies. Low cognitive performance and specific regional FDG-PET hypometabolism at diagnosis are highly suggestive for A + T + or A - T + profiles. This work provides also a realistic picture of the proportion of AD patients eligible for disease modifying treatments emphasizing the need for early detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neuroradiology Unit and High Field MRI Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Förderung
- Ministero della Salute
- Fondation pour la Recherche sur Alzheimer
Zitieren
APA
Canu, E., Rugarli, G., Coraglia, F., Basaia, S., Cecchetti, G., Calloni, S. F., Vezzulli, P. Q., Spinelli, E. G., Santangelo, R., Caso, F., Falini, A., Magnani, G., Filippi, M., & Agosta, F. (2024). Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort. Journal of Neurology. https://doi.org/10.1007/s00415-024-12221-7
Vancouver
Canu E, Rugarli G, Coraglia F, Basaia S, Cecchetti G, Calloni SF, et al. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort. Journal of Neurology. 2024. doi:10.1007/s00415-024-12221-7
BibTeX
@article{Canu2024,
author = {Canu, Elisa and Rugarli, Giulia and Coraglia, Federico and Basaia, Silvia and Cecchetti, Giordano and Calloni, Sonia Francesca and Vezzulli, Paolo Quintiliano and Spinelli, Edoardo Gioele and Santangelo, Roberto and Caso, Francesca and Falini, Andrea and Magnani, Giuseppe and Filippi, Massimo and Agosta, Federica},
title = {Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort},
journal = {Journal of Neurology},
year = {2024},
doi = {10.1007/s00415-024-12221-7}
}
EUVIMED